A Comprehensive Monograph on Gallium Ga-68 Gozetotide (Ga 68 PSMA-11): From Molecular Design to Clinical and Regulatory Integration

Drug Profile and Chemical Characteristics

Gallium Ga-68 gozetotide represents a landmark achievement in the field of nuclear medicine and oncology, providing a highly sensitive tool for the detection and staging of prostate cancer. Its design and function are predicated on the precise integration of a targeting molecule, a stable chelator, and a positron-emitting radionuclide. This section establishes the fundamental identity of the agent, detailing its nomenclature, complex molecular structure, and the critical radiochemical properties that enable its function in positron emission tomography (PET).

Nomenclature and Identification

To navigate the scientific literature and clinical documentation, a clear understanding of the agent's various names is essential. The molecule is known by several identifiers across different regulatory and scientific contexts. Its United States Adopted Name (USAN) is Gallium Ga 68 gozetotide, while its International Nonproprietary Name (INN) is Gallium (68Ga) gozetotide.[1] In clinical and research settings, it is most commonly referred to as

Gallium (68Ga) PSMA-11, acknowledging its target (Prostate-Specific Membrane Antigen) and its specific developmental designation.[1]

Commercially, the agent is marketed under several distinct brand names, reflecting its parallel development and commercialization by different pharmaceutical entities. These include Illuccix, developed by Telix Pharmaceuticals, and Locametz, developed by Advanced Accelerator Applications, a Novartis company.[1] Telix has also introduced a next-generation formulation named

Gozellix.[6] The proliferation of brand names for the same active molecule underscores its clinical importance and the competitive commercial landscape.